Barclays PLC Has $1.62 Million Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Barclays PLC boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 122.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 761,286 shares of the company's stock after purchasing an additional 418,313 shares during the quarter. Barclays PLC owned approximately 0.36% of Allogene Therapeutics worth $1,621,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. abrdn plc acquired a new position in shares of Allogene Therapeutics during the fourth quarter valued at $776,000. Vontobel Holding Ltd. boosted its stake in Allogene Therapeutics by 788.4% during the 4th quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company's stock valued at $416,000 after purchasing an additional 173,457 shares during the period. Sei Investments Co. bought a new position in Allogene Therapeutics in the 4th quarter worth about $103,000. American Century Companies Inc. increased its stake in shares of Allogene Therapeutics by 16.5% in the fourth quarter. American Century Companies Inc. now owns 232,356 shares of the company's stock valued at $495,000 after purchasing an additional 32,935 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of Allogene Therapeutics by 72.6% during the fourth quarter. Intech Investment Management LLC now owns 71,323 shares of the company's stock valued at $152,000 after buying an additional 29,992 shares during the last quarter. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Stock Down 21.0 %

Shares of Allogene Therapeutics stock traded down $0.34 during trading on Tuesday, hitting $1.28. The stock had a trading volume of 5,773,755 shares, compared to its average volume of 3,230,594. Allogene Therapeutics, Inc. has a 1 year low of $1.23 and a 1 year high of $3.78. The stock has a 50 day simple moving average of $1.64 and a 200 day simple moving average of $2.00. The company has a market capitalization of $279.94 million, a PE ratio of -0.82 and a beta of 0.60.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. As a group, equities analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO David D. Chang sold 46,668 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 61,757 shares of company stock valued at $115,873. Corporate insiders own 24.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a research report on Friday, March 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. HC Wainwright decreased their target price on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 19th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Allogene Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $9.29.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).